- Home
- EQS vs CGTX Comparison
EQS vs CGTX Comparison
Compare EQS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- CGTX
- Stock Information
- Founded
- EQS 1991
- CGTX 2007
- Country
- EQS United States
- CGTX United States
- Employees
- EQS N/A
- CGTX N/A
- Industry
- EQS Finance Companies
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- CGTX Health Care
- Exchange
- EQS Nasdaq
- CGTX Nasdaq
- Market Cap
- EQS 14.9M
- CGTX 16.1M
- IPO Year
- EQS N/A
- CGTX 2021
- Fundamental
- Price
- EQS $1.06
- CGTX $0.63
- Analyst Decision
- EQS
- CGTX Strong Buy
- Analyst Count
- EQS 0
- CGTX 6
- Target Price
- EQS N/A
- CGTX $8.30
- AVG Volume (30 Days)
- EQS 13.2K
- CGTX 20.0M
- Earning Date
- EQS 01-01-0001
- CGTX 11-13-2024
- Dividend Yield
- EQS N/A
- CGTX N/A
- EPS Growth
- EQS N/A
- CGTX N/A
- EPS
- EQS N/A
- CGTX N/A
- Revenue
- EQS $1,137,000.00
- CGTX N/A
- Revenue This Year
- EQS N/A
- CGTX N/A
- Revenue Next Year
- EQS N/A
- CGTX N/A
- P/E Ratio
- EQS N/A
- CGTX N/A
- Revenue Growth
- EQS 1795.00
- CGTX N/A
- 52 Week Low
- EQS $1.01
- CGTX $0.34
- 52 Week High
- EQS $1.95
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- EQS 32.54
- CGTX 69.18
- Support Level
- EQS $1.01
- CGTX $0.43
- Resistance Level
- EQS $1.24
- CGTX $1.29
- Average True Range (ATR)
- EQS 0.09
- CGTX 0.10
- MACD
- EQS -0.00
- CGTX 0.03
- Stochastic Oscillator
- EQS 15.62
- CGTX 27.88
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invest primarily in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts and recapitalizations of existing businesses or special situations and achieve capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.